Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 31.95% | 8.47% | -9.23% | -14.99% | -2.82% |
| Total Depreciation and Amortization | -4.76% | -26.33% | 15.20% | 9.89% | 10.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -50.39% | -55.67% | -64.82% | -12.96% | 42.65% |
| Change in Net Operating Assets | 26.35% | 83.22% | 30.65% | 123.74% | 46.25% |
| Cash from Operations | 30.49% | 28.28% | -33.45% | 31.48% | 15.20% |
| Capital Expenditure | -6.39% | -123.61% | -373.95% | -1,588.01% | -48.91% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.46% | -63.75% | 159.89% | -47.61% | 140.32% |
| Cash from Investing | -28.19% | -96.73% | 134.86% | -65.58% | 114.23% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -33.87% | 1,675.38% | 83.54% | -91.07% | -24.87% |
| Repurchase of Common Stock | 25.96% | 49.43% | 92.58% | 49.60% | -20.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -34.18% | 2,332.74% | 109.89% | -91.34% | -25.96% |
| Foreign Exchange rate Adjustments | -141.93% | 148.98% | -154.27% | 691.20% | 203.46% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -40.28% | 110.23% | 139.78% | -141.95% | 237.58% |